Structure Therapeutics Inc. (GPCR)
Nasdaq · Healthcare · Biotechnology
$27.59−0.29%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $2.0B
- 52-week range
- $25.59 – $94.90
- 52-week change
- −2.64%
- EPS (trailing)
- −$3.03
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Net income
- −$141M
- Diluted EPS
- −$0.80
- Free cash flow
- −$226M
From the company’s annual report on SEC EDGAR.
About Structure Therapeutics Inc.
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis.
Headquarters: South San Francisco, United States · 281 employees · structuretx.com